Only in Titles

           Search results for: Recombinant Human Vascular Endothelial Growth Factor rh-VEGF165   

paperclip

#31780671   // Save this To Up

In vivo delivery of VEGF RNA and protein to increase osteogenesis and intraosseous angiogenesis.

Deficient bone vasculature is a key component in pathological conditions ranging from developmental skeletal abnormalities to impaired bone repair. Vascularisation is dependent upon vascular endothelial growth factor (VEGF), which drives both angiogenesis and osteogenesis. The aim of this study was to examine the efficacy of blood vessel and bone formation following transfection with VEGF RNA or delivery of recombinant human VEGF protein (rhVEGF) across in vitro and in vivo model systems. To quantify blood vessels within bone, an innovative approach was developed using high-resolution X-ray computed tomography (XCT) to generate quantifiable three-dimensional reconstructions. Application of rhVEGF enhanced osteogenesis, as evidenced by increased human osteoblast-like MG-63 cell proliferation in vitro and calvarial bone thickness following in vivo administration. In contrast, transfection with VEGF RNA triggered angiogenic effects by promoting VEGF protein secretion from MG-63 cells in vitro, which resulted in significantly increased angiogenesis in the chorioallantoic (CAM) assay in ovo. Furthermore, direct transfection of bone with VEGF RNA in vivo increased intraosseous vascular branching. This study demonstrates the importance of continuous supply as opposed to a single high dose of VEGF on angiogenesis and osteogenesis and, illustrates the potential of XCT in delineating in 3D, blood vessel connectivity in bone.

1458 related Products with: In vivo delivery of VEGF RNA and protein to increase osteogenesis and intraosseous angiogenesis.

Native Influenza HA (A To VEGFB & VEGFA Protein Pro Recombinant Human Androge Native Influenza HA (A To Rabbit Anti-Human Toll In FIV Core Ag, recombinant Rabbit Anti-Rat Androgen Influenza B (B Tokio 53 9 PGF & VEGFA Protein Prote Native Influenza HA (A To Toxoplasma gondii GRA8, r Directed In Vivo Angiogen

Related Pathways

paperclip

#31541344   // Save this To Up

Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms.

Recombinant human vascular endothelial growth factor (rhVEGF) has important applications in therapeutic angiogenesis and inhibition of VEGF-mediated pathological angiogenesis. Previous studies have shown that rhVEGF can be produced in several expression systems, including Escherichia coli, yeasts, insect cells and mammalian cells. However, little is known regarding the effective production of this protein in organs of live organisms. Here, we report for the first time the expression and characterization of rhVEGF165 in the middle silk gland (MSG) of the transgenic silkworm line S1-V165. Our results confirmed that (1) rhVEGF165 was highly expressed in MSG cells and was secreted into the cocoon of S1-V165; (2) the dimeric form of rhVEGF165 could be easily dissolved from S1-V165 cocoons using an alkaline solution; (3) rhVEGF165 extracted from S1-V165 cocoons exhibited slightly better cell proliferative activity than the hVEGF165 standard in cultured human umbilical vein endothelial cells. This study provides an alternative strategy for the production of bioactive rhVEGF165 using the MSG of transgenic silkworms.

2723 related Products with: Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms.

Recombinant Human Interle Recombinant Human Inhibin Recombinant Human Interle Recombinant Human Interle Recombinant Human p16-INK VEGF165, human recombinan Recombinant Human Involuc Recombinant Human Interle Recombinant Human Inhibin Recombinant Human Interle Recombinant Human Interle Recombinant Human Interfe

Related Pathways

paperclip

#29614715   // Save this To Up

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF Neutralization.

Variable new antigen receptor domain (vNAR) antibodies are novel, naturally occurring antibodies that can be isolated from naïve, immune or synthetic shark libraries. These molecules are very interesting to the biotechnology and pharmaceutical industries because of their unique characteristics related to size and tissue penetrability. There have been some approved anti-angiogenic therapies for ophthalmic conditions, not related to vNAR. This includes biologics and chimeric proteins that neutralize vascular endothelial growth factor (VEGF), which are injected intravitreal, causing discomfort and increasing the possibility of infection. In this paper, we present a vNAR antibody against human recombinant VEGF (rhVEGF) that was isolated from an immunized shark. A vNAR called V13, neutralizes VEGF cytokine starting at 75 μg/mL in an in vitro assay based on co-culture of normal human dermal fibroblasts (NHDFs) and green fluorescence protein (GFP)-labeled human umbilical vein endothelial cells (HUVECs) cells. In the oxygen-induced retinopathy model in C57BL/6:Hsd mice, we demonstrate an endothelial cell count decrease. Further, we demonstrate the intraocular penetration after topical administration of 0.1 μg/mL of vNAR V13 by its detection in aqueous humor in New Zealand rabbits with healthy eyes after 3 h of application. These findings demonstrate the potential of topical application of vNAR V13 as a possible new drug candidate for vascular eye diseases.

2337 related Products with: Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF Neutralization.

Resorufin Oleate, Fluorog Human integrin aVb3, affi Directed In Vivo Angiogen MarkerGeneTM in vivo lacZ VEGFB & VEGFA Protein Pro Cultrex In Vitro Angiogen PGF & VEGFA Protein Prote Colon cancer survey tissu Polyclonal Antibody Recep Anti beta3 AR Human, Poly APPL1 & TRAF2 Protein Pro Goat Anti-Human GCH1, (in

Related Pathways

paperclip

#29468155   // Save this To Up

A Low Cost Implantation Model in the Rat That Allows a Spatial Assessment of Angiogenesis.

There is continual demand for animal models that allow a quantitative assessment of angiogenic properties of biomaterials, therapies, and pharmaceuticals. In its simplest form, this is done by subcutaneous material implantation and subsequent vessel counting which usually omits spatial data. We have refined an implantation model and paired it with a computational analytic routine which outputs not only vessel count but also vessel density, distribution, and vessel penetration depth, that relies on a centric vessel as a reference point. We have successfully validated our model by characterizing the angiogenic potential of a fibrin matrix in conjunction with recombinant human vascular endothelial growth factor (rhVEGF165). The inferior epigastric vascular pedicles of rats were sheathed with silicone tubes, which were subsequently filled with 0.2 ml of fibrin and different doses of rhVEGF165, centrically embedding the vessels. Over 4 weeks, tissue samples were harvested and subsequently immunohistologically stained and computationally analyzed. The model was able to detect variations over the angiogenic potentials of growth factor spiked fibrin matrices. Adding 20 ng of rhVEGF165 resulted in a significant increase in vasculature while 200 ng of rhVEGF165 did not improve vascular growth. Vascularized tissue volume increased during the first week and vascular density increased during the second week. Total vessel count increased significantly and exhibited a peak after 2 weeks which was followed by a resorption of vasculature by week 4. In summary, a simple implantation model to study vascularization with only a minimal workload attached was enhanced to include morphologic data of the emerging vascular tree.

1454 related Products with: A Low Cost Implantation Model in the Rat That Allows a Spatial Assessment of Angiogenesis.

Multiple organ tumor tiss Directed In Vivo Angiogen Angiogenesis (Human) Anti Brain-Specific Angiogenes FDA Standard Frozen Tissu Thermal Shaker with cooli Angiogenesis (Human) Anti FDA Standard Frozen Tissu Cultrex In Vitro Angiogen FDA Standard Frozen Tissu Angiogenesis (Human) Anti FDA Standard Frozen Tissu

Related Pathways

paperclip

#28778505   // Save this To Up

Lipoprotein Receptor-related Protein 6 Signaling is Necessary for Vasculogenic Differentiation of Human Dental Pulp Stem Cells.

The aim of this study was to evaluate the effects of Wnt signaling through lipoprotein receptor-related protein 6 (LRP6) and Frizzled6 on the endothelial differentiation of dental pulp stem cells (DPSCs). DPSCs were stably transduced with enhanced green fluorescent protein (EGFP)-tagged lentiviral vectors (short hairpin RNA-LRP6, short hairpin RNA-Frizzled6, or empty vector controls). We evaluated the effects of LRP6 and Frizzled6 on expression of endothelial markers and on capillary tube formation mediated by DPSCs induced with recombinant human Wnt1 (rhWnt1) and/or recombinant human vascular endothelial growth factor (rhVEGF). In vivo, tooth slices/scaffolds were seeded with LRP6-silenced, Frizzled6-silenced, or vector control DPSC cells and transplanted into immunodeficient mice. The density of blood vessels generated by DPSCs differentiated into vascular endothelial cells was analyzed by immunohistochemistry for EGFP. The rhWnt1 and rhVEGF induced expression of active β-catenin in control DPSCs and in Frizzled6-silenced DPSCs, but not in LRP6-silenced DPSCs. Furthermore, VEGF and interleukin-8 were downregulated in LRP6-silenced DPSCs, but not in control DPSCs or in Frizzled6-silenced DPSCs (P < .05). Likewise, rhWnt1 and rhVEGF induced expression of the endothelial marker VEGF receptor-2 in control DPSCs and in Frizzled6-silenced DPSCs, but not in LRP6-silenced DPSCs. These data correlated with a trend for lower density of capillary sprouts generated by LRP6-silenced DPSCs when compared with control DPSCs in Matrigel. In vivo, tooth slice/scaffolds seeded with DPSC-short hairpinRNA-LRP6 cells showed lower density of human blood vessels (ie, EGFP-positive blood vessels), when compared with tooth slice/scaffolds seeded with vector control cells (P < .05). Collectively, these data demonstrated that LRP6 signaling is necessary for the vasculogenic differentiation of human DPSCs.

2999 related Products with: Lipoprotein Receptor-related Protein 6 Signaling is Necessary for Vasculogenic Differentiation of Human Dental Pulp Stem Cells.

Primary antibody low den NATIVE HUMAN PROLACTIN, P NATIVE HUMAN PROLACTIN, P Rabbit Anti-TNIP2 ABIN2 T Human, Adipophilin (Adipo Human dopachrome tautomer Rabbit Anti-IEX1 Differen Rabbit Anti-TNIP2 ABIN2 T Mouse Anti-Human LDL Rece Rabbit Anti-IEX1 Differen Rabbit Anti-SEC14 like pr G protein-coupled recepto

Related Pathways

paperclip

#28453232   // Save this To Up

Repair of large saddle defects of the mandibular ridge using dual growth factor release-An experimental pilot study in minipigs.

To test the hypothesis that the addition of small amounts of rhVEGF to rhBMP2 in a polymer carrier can accomplish equivalent repair effect as a reduced dosage of rhBMP2 compared to rhBMP2 alone.

1542 related Products with: Repair of large saddle defects of the mandibular ridge using dual growth factor release-An experimental pilot study in minipigs.

IGF-1R Signaling Phospho- Hamster anti mouse Insuli Rat monoclonal anti mouse Mouse Anti-Insulin-Like G Rat monoclonal anti mouse Rat monoclonal anti mouse Growth Factor (Human) Ant Goat Anti-Human Fibroblas Rat monoclonal anti mouse Rat monoclonal anti mouse TGF beta induced factor 2 Multiple organ tumor tiss

Related Pathways

paperclip

#27663536   // Save this To Up

The Use of Sequential VEGF- and BMP2-Releasing Biodegradable Scaffolds in Rabbit Mandibular Defects.

Promising developments have materialized in reconstructive surgical procedures with the applications of tissue engineering. In our study, we used tissue scaffolds fabricated from polylactic acid-polyethylene glycol (PLLA-PEG) copolymers to ensure different release rates of selective growth factors recombinant human bone morphogenetic protein 2 [rhBMP-2] and vascular endothelial growth factor (rhVEGF165) in the repair of mandibular bone defects.

2771 related Products with: The Use of Sequential VEGF- and BMP2-Releasing Biodegradable Scaffolds in Rabbit Mandibular Defects.

Rabbit Anti-NOS-2 iNOS Po Rabbit Plasma US Origin I Rabbit Anti-BMP2 Polyclon Rabbit Anti-Integrin beta Rabbit Anti-Insulin Recep Rabbit Plasma US Origin I Rabbit Anti-BMP2 Polyclon Proteasome inhibitor PI31 Rabbit Anti-Integrin alph Rabbit Anti-Trypsin Inhib Rabbit Anti-Integrin beta Rabbit Anti-Integrin alph

Related Pathways

paperclip

#26485046   // Save this To Up

Continuous delivery of rhBMP2 and rhVEGF165 at a certain ratio enhances bone formation in mandibular defects over the delivery of rhBMP2 alone--An experimental study in rats.

The aim of the present study was to test the hypothesis that different amounts of vascular endothelial growth factor and bone morphogenic protein differentially affect bone formation when applied for repair of non-healing defects in the rat mandible. Porous composite PDLLA/CaCO3 carriers were fabricated as slow release carriers and loaded with rhBMP2 and rhVEGF165 in 10 different dosage combinations using gas foaming with supercritical carbon dioxide. They were implanted in non-healing defects of the mandibles of 132 adult Wistar rats with additional lateral augmentation. Bone formation was assessed both radiographically (bone volume) and by histomorphometry (bone density). The use of carriers with a ratio of delivery of VEGF/BMP between 0.7 and 1.2 was significantly related to the occurrence of significant increases in radiographic bone volume and/or histologic bone density compared to the use of carriers with a ratio of delivery of ≤ 0.5 when all intervals and all outcome parameters were considered. Moreover, simultaneous delivery at this ratio helped to "save" rhBMP2 as both bone volume and bone density after 13 weeks were reached/surpassed using half the dosage required for rhBMP2 alone. It is concluded, that the combined delivery of rhVEGF165 and rhBMP2 for repair of critical size mandibular defects can significantly enhance volume and density of bone formation over delivery of rhBMP2 alone. It appears from the present results that continuous simultaneous delivery of rhVEGF165 and rhBMP2 at a ratio of approximately 1 is favourable for the enhancement of bone formation.

1598 related Products with: Continuous delivery of rhBMP2 and rhVEGF165 at a certain ratio enhances bone formation in mandibular defects over the delivery of rhBMP2 alone--An experimental study in rats.

Goat Anti-Human ATP13A1, MAPK3 & ATF2 Protein Prot FDA Standard Frozen Tissu Goat Anti- Atoh7 (zebrafi Goat Anti- ATP7A, (intern Goat Anti-Mouse ATG16L1, FDA Standard Frozen Tissu ATF4 & JUN Protein Protei Goat Anti- ATAD5 FRAG1, ( Goat Anti-Human ATGL Desn Atherosclerosis (Mouse) A Multiple organ tumor tiss

Related Pathways

paperclip

#25848271   // Save this To Up

Angiogenesis and bone regeneration of porous nano-hydroxyapatite/coralline blocks coated with rhVEGF165 in critical-size alveolar bone defects in vivo.

To improve the regenerative performance of nano-hydroxyapatite/coralline (nHA/coral) block grafting in a canine mandibular critical-size defect model, nHA/coral blocks were coated with recombinant human vascular endothelial growth factor(165) (rhVEGF) via physical adsorption (3 μg rhVEGF165 per nHA/coral block). After the nHA/coral blocks and VEGF/nHA/coral blocks were randomly implanted into the mandibular box-shaped defects in a split-mouth design, the healing process was evaluated by histological observation and histomorphometric and immunohistological analyses. The histological evaluations revealed the ingrowth of newly formed blood vessels and bone at the periphery and cores of the blocks in both groups at both 3 and 8 weeks postsurgery, respectively. In the histomorphometric analysis, the VEGF/nHA/coral group exhibited a larger quantity of new bone formation at 3 and 8 weeks postsurgery. The percentages of newly formed bone within the entire blocks in the VEGF/nHA/coral group were 27.3% ± 8.1% and 39.3% ± 12.8% at 3 weeks and 8 weeks, respectively, and these values were slightly greater than those of the nHA/coral group (21.7% ± 3.0% and 32.6% ± 10.3%, respectively), but the differences were not significant (P>0.05). The immunohistological evaluations revealed that the neovascular density in the VEGF/nHA/coral group (146 ± 32.9 vessel/mm(2)) was much greater than that in the nHA/coral group (105 ± 51.8 vessel/mm(2)) at the 3-week time point (P<0.05), but no significant difference was observed at the 8-week time point (341 ± 86.1 and 269 ± 50.7 vessel/mm(2), respectively, P>0.05). The present study indicated that nHA/coral blocks might be optimal scaffolds for block grafting in critical-size mandibular defects and that additional VEGF coating via physical adsorption can promote angiogenesis in the early stage of bone healing, which suggests that prevascularized nHA/coral blocks have significant potential as a bioactive material for bone regeneration in large-scale alveolar defects.

1181 related Products with: Angiogenesis and bone regeneration of porous nano-hydroxyapatite/coralline blocks coated with rhVEGF165 in critical-size alveolar bone defects in vivo.

Bone marrow tumor and nor Bone marrow tumor and adj Human normal bone and ost Bone cancer test tissue a Directed In Vivo Angiogen Alkaline Phospatase (ALP) Bone and cartilage cancer Bone and cartilage tumor Incu Tissue(square vessel Angiogenesis (Mouse) Anti Brain Specific Angiogenes Phosphatase Inhibitor (So

Related Pathways

paperclip

#25607471   // Save this To Up

Recombinant human vascular endothelial growth factor receptor 1 effectively inhibits angiogenesis in vivo.

Vascular endothelial growth factor (VEGF) plays an important role in both physiological and pathological angiogenesis. VEGF receptor‑1 (VEGFR‑1) acts as a decoy VEGF receptor that enables the regulation of VEGF on the vascular endothelium. In the present study, the recombinant human VEGFR1D1‑3/Fc (rhVEGFR‑1), which contains key domains for VEGF binding, was cloned and expressed in Chinese hamster ovary (CHO) cells. The rhVEGFR‑1 protein was purified using protein‑A affinity chromatography. The molecular weight of rhVEGFR‑1 was found to be ~162 and 81 kD in non‑reducing and reducing SDS‑PAGE, respectively. The majority of the final protein products were in the dimeric conformation. Western blot analysis revealed that rhVEGFR‑1 was only capable of binding to the full glycan form of rhVEGF‑165 and rhVEGF‑121. The dissociation constant for the binding of rhVEGFR‑1 to VEGF‑165, detected using Biacore, was 285 pM. In addition, rhVEGFR‑1 inhibited the proliferation and migration of human microvascular endothelial cells. In vivo experiments also demonstrated that rhVEGFR‑1 inhibited chicken chorioallantoic membrane neovascularization and angiogenesis in nude mice. In conclusion, an anti‑angiogenic recombinant soluble VEGFR was expressed (up to 5 mg/l) in CHO cells and was shown to be capable of inhibiting neovascularization in vivo and in vitro.

2985 related Products with: Recombinant human vascular endothelial growth factor receptor 1 effectively inhibits angiogenesis in vivo.

Recombinant Human Vascula Human Vascular Endothelia Human Vascular Endothelia Growth Differentiation Fa Human Insulin-like Growth Human Endocrine Gland Vas Recombinant Human Androge Macrophage Colony Stimula Goat Anti-Human Fibroblas Recombinant Human Endothe Mouse Insulin-like Growth Recombinant Human Factor

Related Pathways